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Simple Summary: Optimal cancer treatment requires the selection of patients based on the character-
istics of their tumors. This review explores various strategies to select patients for DNA double strand
break-inducing agents, such as PARP inhibitors. Patients with germline BRCA1/2 mutations benefit
from these inhibitors. However, patients with a functional defect in the homologous recombination
repair pathway without germline BRCA1/2 mutations also show a similar reaction to this treatment.
The challenge is to identify the patients with BRCA-like tumors. Here, we review various strategies
to select this group of patients and summarize the clinical evidence for their performance.
Abstract: Germline BRCA mutations result in homologous recombination deficiency (HRD) in
hereditary breast and ovarian cancer, as well as several types of sporadic tumors. The HRD phenotype
makes these tumors sensitive to DNA double strand break-inducing agents, including poly-(ADP-
ribose)-polymerase (PARP) inhibitors. Interestingly, a subgroup of cancers without a BRCA mutation
also shows an HRD phenotype. Various methods for selecting patients with HRD tumors beyond
BRCA-mutations have been explored. These methods are mainly based on DNA sequencing or
functional characteristics of the tumor. We here discuss the various tests and the status of their
clinical validation.
Keywords: HRD; BRCAness; DNA repair; PARP inhibitors; DNA double strand breaks
1. Homologous Recombination Deficiency and Cancer
The discovery of new biomarkers of tumor treatment response is the focus of many
studies. Several markers have made it to the clinic, such as hormone receptor status
for breast and prostate cancer. However, most anti-cancer drugs are prescribed based
on overall efficacy in particular tumor types without preselection based on predictive
biomarkers. Developing biomarkers to select the best treatment for each patient should
increase patient prognosis and decrease unnecessary side effects and costs.
In this review, we describe methods to select patients who might benefit specifically
from a specific class of DNA damaging agents that induce double strand DNA breaks
(DSB), including platinum salts and poly-(ADP-Ribose)-polymerase inhibitors (PARPi).
These DSB require homologous recombination (HR) for their repair [1,2]. Patients with a
germline mutation in the breast cancer susceptibility genes Breast cancer 1 (BRCA1) or Breast
cancer 2 (BRCA2) have a high risk of developing breast cancer or ovarian cancer [3] and
show high sensitivity to these DNA damaging agents [4,5]. As both BRCA1 and BRCA2
proteins are involved in HR [6,7], tumors without BRCA gene mutations but with a similar
homologous recombination deficiency (HRD) phenotype are expected to show similar
responses to DSB-inducing drugs. Currently, germline BRCA (gBRCA) mutated ovarian
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and breast cancer patients are eligible for PARPi treatment, but a clinically validated test to
select HRD tumors (also called BRCA-like tumors) is not yet available.
HR mediates error-free repair of DSBs that arise during DNA replication [8]. BRCA1
is attracted to DNA ends, where it stimulates exonucleases that create a single strand (ss)
overhang by 5′-3′ end resection (Figure 1). RPA binds to the ssDNA and is subsequently
replaced by RAD51 protein. This exchange reaction requires a complex containing RAD51,
BRCA2, and PALB2. After formation of the RAD51-DNA filament, the single strand
overhang searches for homology in the sister chromatid, that functions as the template for
DNA repair. As HR uses the newly formed sister chromatid as a template, it is restricted to
the S and G2 phases of the cell cycle [7].
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Figure 1. Simplified scheme of the homologous recombination pathway. After attraction of BRCA1
to the DNA ends, it stimulates exonuclease to create single-strand overhangs by 5′-3′ end res ction.
RPA binds to this single strand DNA. Subsequently, RAD51 replaces RPA, a reaction that als requires
BRCA2 and PALB2. This DN -RAD51 filament searches for homology in the sister chromatid that is
subsequently used as template for DNA repair.
DNA repair defects have been described as ‘enabling characteristics of cancer’ [9].
This means that defects such as HRD promote tumorigenesis by increasing the speed of
mutation accumulation in a cell on its way to become a cancer cell. The DNA repair defect
is often an early event in tumor evolution and the defect is present in the large majority, if
not all, of the cells in the tumor. Therefore, HRD is a promising therapeutic target.
2. Various Ways to Define HRD
In the search for BRCA-like tumors, several tests have been designed to recognize
them. Most tests are based on sequencing of the tumor compared to germline DNA. The
most obvious test is sequencing of the known disease-causing genes, i.e., BRCA1 and
BRCA2. As an extension of this approach, panels of multiple genes can be chosen based
on their involvement in the HR pathway, such as PALB2 or RAD51 (Figure 1; see Section 3
for examples).
Sequencing can also be used in the search for so-called genomic scars. These are specific
types of genomic changes that are a direct or indirect consequence of the DNA repair defect,
which accumulate over the course of tumor evolution (examples in Section 5).
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Alternative tests are based on the loss and amplification of pieces of chromosomes
or whole chromosomes. The basic idea behind these tests is that HRD tumors are often
accompanied by very specific chromosomal alterations that confer a selective advantage in
combination with BRCA gene mutations and the HRD phenotype, which can therefore be
used as a way to identify BRCA-like tumors. These chromosomal gains and losses lead
to changes in gene expression, which presents another possible way of identifying HRD
tumors (examples in Sections 4, 6 and 7).
Section 8 covers functional assays, which present a completely different approach.
These assays directly investigate functional parameters in fresh tumor specimens. In
general, a fresh tumor part receives a relevant treatment ex vivo and the response is
measured to assess whether the tumor is HRD and thus BRCA-like.
The various ways of selecting patients require different starting material (Figure 2)
and are described in more detail below. In addition to the analytical validity of such
potential biomarkers for BRCA-like tumors, we describe the available clinical validation of
the individual HRD tests.
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Figure 2. Homol gous recombination deficiency (HRD) biomarkers and material needed to analyze the
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frozen material; HR= homologous recombination.
3. Panel Sequencing of Potential Causal Genetic Changes in HR Genes
HRD can not only be caused by i , t also by mu-
tations in other HR genes. Th refore, sequencing of a panel of candidate HR genes is a
possible method to select BRCA-like tumors. Mutatio s in the PALB2 gene are a k own
cause of hereditary breast cancer and ovarian cancer, and have been found in 0.1–2.7% of
unselected Breast Cancer (BrC) patients [10]. Other genes have been selected based on their
known role in the HR pathway, such as RAD51 or RAD54. The selection of HR associated
genes can differ between panels.
As a first evaluation of this approach, a panel of 102 HR pathway related genes
was analyzed across various cancer types using data available from The Cancer Genome
Atlas (TCGA). Bi-allelic mutations in HR-related genes were compared to features of HRD
deduced from alterations throughout the genome [11]. The authors found significant
correlation between biallelic pathological gene alterations and mutation patterns which
have also been shown to be associated with mutations in BRCA1/2 genes. Moreover, in a
cohort of ovarian cancer patients treated with carboplatin, the biallelic alterations were
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clearly associated with a longer overall survival, suggesting that the gene panel approach
indeed selects BRCA-like tumors (also referred to as BRCAness).
Further clinical evidence for the predictive value of the HRD test based on mutations
in HR genes came from studies in patients with castration-refractory prostate cancer (CRPC;
Table 1). In a single-arm phase 2 study, a mutation in one of the 113 non-BRCA HR-related
genes in tumor tissue of CRPC patients was associated with a high combined response rate
(CCR) to olaparib (7/9 = 78%) [12]. In the larger TOPARP-B phase 2 study, the overall CCR
among CRPC patients with HR-related gene mutations was lower (20/66 = 30.3%) [13].
Analysis of subgroups with mutations in single HR genes showed higher CCR in some
(ATM or PALB2 gene mutations), but lower CCR in other subgroups (e.g., CDK12 gene
mutations). Recently, the results of the randomized phase 3 PROfound study in patients
with CRPC, comparing the effectiveness of olaparib with enzalutamide or abiraterone,
were published [14]. Tumors with mutations in at least one out of 15 HR-related genes were
expected to benefit more from olaparib than from enzalutamide or abiraterone. Although
the primary endpoint, imaging-based progression-free survival (iPFS), was higher for
olaparib than enzalutamide in patients with a BRCA1/2 or an ATM mutation (iPFS of 7.4
versus 3.6 months; HR 0.34 (0.25–0.47)), this was not the case in patients with mutations
in other HR-related genes (estimated iPFS of around 2.8 vs. 3.2 months). In addition,
subgroup analysis in patients with only an ATM mutation showed no preferential benefit of
olaparib treatment compared to enzalutamide or abiraterone. This suggests that the longer
iPFS on olaparib in patients with HR-related gene mutations compared to enzalutamide or
arbiraterone is mainly determined by the tumors with a BRCA1/2 mutation, rather than
tumors with mutations in non-BRCA HR-related genes. Based on these studies in CRPC
patients, it is uncertain whether tumors with HR-related mutations other than BRCA1/2 are
truly HRD. Further investigation is required to determine which non-BRCA CRPC patient
will benefit of PARPi treatment.
HR-related gene panels as a biomarkers for HRD have also been investigated in breast
cancer patients, with somewhat conflicting results (Table 1). First-line gemcitabine/cisplatin
(GP) treated metastatic triple negative breast cancer patients showed longer PFS than
gemcitabine/paclitaxel (GT) treated patients in the subgroup with proven germline HR-
related mutations in the randomized phase 3 CBCSG006 study (PFS 10.4 vs. 4.3 months
respectively, p = 0.011) [15]. Even after excluding patients with a germline BRCA1/2
mutation, this difference remained (estimated PFS of 10.9 vs. 4.7 months). In line with
these findings, Tung et al. showed in the small TBCRC 048 study among patients with pre-
treated metastatic breast cancer that 33% (9/27) of the patients with a germline HR-related
gene mutation showed an objective response to olaparib monotherapy [16]. Remarkably,
all patients with a response turned out to be patients with a germline PALB2 mutation.
However, somatic HR-related gene mutations, even somatic PALB2 or BRCA1/2 mutations,
did not have predictive value for a response to olaparib (objective response rate 0% (0/10))
in this pretreated patient population. This may be different for treatment-naïve tumors
given the findings of the PETREMAC study [17]. In this small neoadjuvant study among
32 triple negative breast cancer patients, somatic mutations in non-BRCA1/2 HR-related
genes were found to be predictive for a response to olaparib (objective response rate 100%
(5/5)).
Finally, HR-related gene panels were examined in two studies among patients with
ovarian cancer (Table 1) [18,19]. In both studies, the presence of somatic HR-related
gene mutations other than BRCA1/2 mutations had predictive value. In the prospective
cohort study in which patients with primary ovarian cancer were treated with adjuvant
carboplatin/paclitaxel, platinum sensitivity was found to be greater among tumors with
an HR-related gene mutation compared to those without such a mutation [19]. Even in
patients with extensively pretreated ovarian carcinoma, olaparib was found to be of added
value over placebo in patients with somatic HR-related gene mutation [18].
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Table 1. Clinical studies investigating the predictive value of HRD measured by HR-related gene panels.
Type of Study + Ref. Patients Number of Genes in Panel +Definition HRD
Subgroups and Distribution of
Mutations
Treatment
(Number Treated) Primary Endpoint and Results
TOPARP A trial
phase 2; single arm [12]
Men with metastatic
castration-resistant prostate cancer
who had disease progression after
one or two regimens of
chemotherapy
113 gene panel on tumor samples
HRD: homozygous deletion or
deleterious mutation or both in ≥1
HRR genes
16/49 (33%) HRD: 7× BRCA2, 5×
ATM, 3× FANCA, 2× CHEK2, all
others genes 1×
Olaparib 400 mg bid (n = 50)
PE: RR defined as CR/PR (RECIST 1.1) or
50% decrease in PSA or CTC count <
5CTCs/7.5 mL
Overall RR 16/49 (33%)
RR in HRD: 14/16 (88%)
RR in HRD excluding BRCA1/2: 7/9 (78%)
RR in ATMm only 4/5 (80%)
RR in FANC2/3m only (67%)





who have been treated with one or
two taxane regimens
113 gene panel on tumor samples
HRD: aberrations in ≥1 HRR genes
161/592 (27%) HRD: 44× BRCA2;
40× ATM, 33× CDK12
Of all 161 HRD patients, 98
participated in the study of whom:
32× BRCA1/2, 21× ATM; 20× CDK12;
7× PALB2; 18× other
Olaparib 400 mg bid (n = 49)
vs.
olaparib 300 mg bid (n = 49)
PE: CCR defined as CR/PR (RECIST 1.1)
or 50% decrease in PSA or CTC count <
5CTCs/7.5 mL
In both (300 + 400 mg) cohorts together:
CCR BRCA1/2m: 83.3% (25/30); PFS 8.3
months
CCR non-BRCA HRD group: 30.3%
(20/66)
CCR PALB2m only: 57.1% (4/7); PFS 5.3
months
CCR ATMm only: 36.8% (7/19); PFS 5.8
months
CCR CDK12m only; 25% (5/20); PFS 2.8
months
CCR of other gene mutations: 20% (2/10)
PROFOUND study





during enzalutamide or abiraterone
treatment
15 genes panel on tumor samples
HRD: suspected deleterious
alterations in at least 1 gene
Cohort A: at least one alteration in
BRCA1/2, or ATM
Cohort B: at least one alteration in








nzalutamide or abiraterone (2:1)
PE: iPFS, median FU between 5.4–7.5
months
Cohort A (n = 256)
iPFS 7.4 vs. 3.6 months; HR 0.34
(0.25–0.47)
Cohort B (n = 142)
* estimated iPFS 2.8 vs. 3.2 months
iPFS ATMm only (n = 86):
5.4 vs. 4.7 months; HR 1.04 (0.61–1.87)
iPFS CDK12m only (n = 89):
5.1 vs. 2.2 months; HR 0.74 (0.44–1.31).
CBCSG006 trial
Randomized phase 3;
post-hoc biomarker analyses [15]
Advanced TNBC, first line, no
genomic preselection
28 genes panel in blood samples.
HRD defined as at least one gHRR
gene mutations
Two groups
I: HRD (incl. gBRCA1/2; n = 63)
II: no HRD (n = 69)
Main gene mutations: 14× BRCA1/2,
10× BARD1, 9× ATM, 6× BRIP1, 6×
RAD51C/D, 26× FANC, 5× PALB2,
CDH1, MSH2/6, 3× CHEK2
Paclitaxel/gemcitabine (GP, n = 68)
vs.
cisplatin/gemcitabine (GT, n = 64)
PE: PFS; median FU 54.7 months
Group I
HRD (incl. gBRCA1/2m): PFS: GP vs. GT
10.4 vs. 4.3 months (p = 0.011)
HRD (excl. gBRCA1/2m): * estimated PFS:
GP vs. GT: 10.9 vs. 4.7 months
Group II; no HRD: PFS GP vs. GT: 6.0 vs.
7.1 months (p = 0.154)
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Table 1. Cont.
Type of Study + Ref. Patients Number of Genes in Panel +Definition HRD
Subgroups and Distribution of
Mutations
Treatment
(Number Treated) Primary Endpoint and Results
TBCRC 048
phase 2, single arm [16]
Metastatic breast cancer, maximum of
2 lines of chemotherapy for advanced
disease, no prior PARPi or
progression on platinum, and a
mutation ≥1 g/sHRRm
20 genes panel on tumor samples and
in blood
HRD: mutation in ≥1 s/g HRR genes
Cohort 1:
Germline mutation in gHRRm genes
(excl. gBRCA1/2m); n = 27
Cohort 2:
Somatic mutations in HRR genes
(incl. sBRCA1/2m); n = 27
Olaparib 300 mg bid (n = 54)
PE: ORR = PR or CR according to RECIST
v1.1
Cohort 1
ORR (gHRRm, excl. gBRCA1/2m) 33%
(9/27); all 9 had gPALB2m
ORR in gPALB2m only: 82% (9/11)
Cohort 2
ORR (sHRRm; incl. sBRCA1/2m): 31%
(8/26)
ORR (sHRRm, excl. sBRCA1/2m): 0%
(0/10)
Pretermac study
Neoadjuvant study, single arm,
post-hoc biomarker analyses in
TNBC only [17]
Stage II-II primary breast cancer,
subset TNBC only
360 genes panel on tumor samples
among which HRR genes.
HRD: not specifically defined
Three subgroups
I all TNBC excl. gBRCA1/2m and
gPALB2mII g/sBRCAm and gPALBm2
only
III sHRRm (excl. g/sBRCAm)
Main gene mutations 6× g/s
BRCA1/2,
1× gPALB2;
5× non-BRCA sHRR gene mutation
(16%): all 1× ATR, EMSY, MEN1,
SETD2, PTEN
Olaparib
300 mg bid for up to 10 weeks (n = 32)
PE: ORR = PR or CR according to
RECIST1.1
ORR all TNBC: 56.3% (18/32)
I ORR all TNBC excl. gBRCA1/2m and
gPALB2m: 51.9% (14/27)
II: ORR g/sBRCAm and gPALBm2 only:
83% (5/6)
III: ORR non-BRCA sHRRm: 100% (5/5)
Study 19
Randomized phase 2; post-hoc
biomarker analyses [18]
Platinum sensitive grade 2/3 serous
ovarian carcinoma, platinum
sensitive, 2–3 lines of platinum and
an objective response on last
platinum-based therapy
287 cancer related genes + select
introns from 27 HRR genes +
gBRCA1/2 testing
HRD: not specifically defined
Four subgroups (n = 209)
I: g/s BRCAm (n = 111);
II: g/sBRCAwt + sHRRm (n = 21);
III: g/sBRCAwt + sHRR mutation
unknown (n = 16)
IV: g/sBRCAwt en sHRRwt (n = 58)
209/265 (79%)
Olaparib 400 mg bid vs.
placebo as maintenance therapy
PE: PFS olaparib versus placebo
PFS in subgroups
I: HR 0.16 (0.08–0.30)
II: HR 0.21 (0.04–0.86)
III: not mentioned
IV: HR 0.71 (0.37–1.35)
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Table 1. Cont.
Type of Study + Ref. Patients Number of Genes in Panel +Definition HRD
Subgroups and Distribution of
Mutations
Treatment
(Number Treated) Primary Endpoint and Results
Prospective cohort study;
post hoc biomarker analyses in
subgroup of primary tumors
only [19]
Ovarian, fallopian tube, or primary
peritoneal carcinoma (primary (n =
304), recurrent (n = 34), paired
primary and recurrent (n = 24)
13 gene panel in blood and tumor
samples.
HRD: a deleterious germline and/or






32× (26%) in the other





treatment (n = 304)
PE: platinum sensitivity (PS) defined as
complete response (CR) during adjuvant
chemotherapy maintenance of CR >6
months post completion chemotherapy.
Analysis in 243 patients with sufficient
clinical response data
PPS in gBRCA1/2m: 81% (38/47)
PPS in g/sHRRm (excl. gBRCA1/2m, incl.
sBRCA1/2m) 87% (33/38)
PPS in g/sHRRm (excl. g/sBRCA1/2m):
78% (14/18)
PPS in non-HRD: PPS 60% (95/158)
Bid = twice daily; CCR = confirmed composed response; FU = follow-up; g = germline; HRD homologous recombination deficiency; HR = homologous recombination related; iPFS = imaging-based
progression-free survival; ORR = objective response rate; PE = primary endpoint; PFS = progression free survival; s = somatic; TNBC = triple negative breast cancer; wt = wild type; * estimated only in case this
was possible on the basis of existing data.
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In conclusion, the gene panel approach appears to have benefits for identifying BRCA-
like tumors, although more research is needed to determine which genes should be included
in this analysis.
4. Chromosomal Aberrations as a Consequence of HRD
HR is required to maintain chromosomal integrity by the precise repair of DSBs.
Defects in this repair pathway result in imprecise repair and loss of chromosomal sequences,
also referred to as loss of heterozygosity (LOH), as well as structural rearrangements (such
as translocations). The level of chromosomal aberrations has therefore been suggested to
correlate with HRD status.
Attempts to preselect HRD tumors based on the level of LOH throughout the genome
has been described in the ARIEL2 (phase 2; single arm [20]) and ARIEL3 (phase 3; placebo-
controlled [21]) studies, that examined the effect of the PARPi rucaparib in platinum-
sensitive ovarian cancer (Table 2). Within the studies, three subgroups were defined: the
BRCA mutated group, the non-BRCA mutated LOH-high group (HRD defined as LOH
>14% (ARIEL 2) or LOH >16% (ARIEL 3)) and the non-BRCA mutated LOH-low group.
In the ARIEL3 trial, the effect of rucaparib was clearly greatest in the BRCA1/2 mutant
group (16.6 months compared to 5.4 months in the placebo group). Although there was
a statistically significant added value of rucaparib in the other two groups compared to
placebo, the absolute median PFS increase was smaller than in the BRCA mutated group
(Table 2). This suggests that the discriminating power of the LOH testing for selecting
HRD tumors in ovarian cancer patients is suboptimal, as all groups benefited significantly
compared to placebo. This is in line with the results of the small phase 2 PrECOG study of
triple negative breast cancer patients. Tumors with high LOH (n = 50) showed a 66% chance
of a good tumor reduction (residual cancer burden [RCB] 0/1) in response to neoadjuvant
chemotherapy consisting of carboplatin, gemcitabine, and iniparib. However, one in five
women with low LOH tumors (n = 15) also showed a RCB0/1 response after neoadjuvant
chemotherapy [22].
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Table 2. Clinical studies investigating the predictive value of HRD measured by loss of heterozygosity (LOH) or chromosomal aberrations.
Type of Study + ref. Patients Test Used + Definition HRD Subgroups Treatment(Total Treated) Primary Endpoint and Results
LOSS OF HETEROZYGOSITY (LOH)
ARIEL2 study, phase 2, single arm
[20]
Recurrent, platinum sensitive
(minimal 1 line platinum-based CTx
and PFI >6 months after last
platinum dose), high grade serous or
endometrioid ovarian, fallopian, or
primary peritoneal carcinoma
LOH by Next Generation Sequencing
(NGS)
HRD = LOH high, i.e., genomic LOH
≥14% on archival or pretreatment
biopsies
Three groups
I: g/s BRCA1/2m (n = 40);
II: g/sBRCA1/2wt + LOH high (n =
82);
III: g/sBRCA1/2wt + LOH low (n =
70)
Rucaparib (n = 192)
PE: PFS
I vs. II vs. III: PFS 12.8 vs. 5.7 vs. 5.2
months
I vs. III HR PFS 0.27 (0.16–0.44)
II vs. III HR PFS 0.63 (0.42–0.90)
ARIEL3
Randomized phase 3 [21]
Recurrent, platinum sensitive
(minimal 2 line platinum-based
therapy and PFI >6 months after last
platinum dose), high grade serous or
endometrioid ovarian, fallopian, or
primary peritoneal carcinoma
LOH by NGS
HRD = LOH high, i.e., genomic LOH
score ≥16% on archival or
pretreatment biopsies
Three subgroups
I: g/s BRCAm (n = 196);
II: BRCAwt + LOH high (n = 158);
III: BRCAwt + LOH low (n = 210)
Rucaparib (n = 375) vs.
placebo
(n = 189)
PE: iaPFS rucaparib vs. placebo
I: iaPFS; 16.6 vs. 5.4 months; HR 0.23
(0.16–0.34)
II: iaPFS: 9.7 vs. 5.4 months; HR 0.44
(0.29–0.66)
III: iaPFS: 6.7 vs. 5.4 months; HR 0.58
(0.40–0.85)
PrECOG trial
Neoadjuvant, Phase 2, single arm [22] Primary triple negative breast cancer
LOH
DNA copy number was determined
using genome-wide SNP data
HRD = LOH-high, i.e., LOH score of
≥10% in pre-treatment breast
biopsies
Two groups
I: HRD: LOH high (n = 50)
II: no-HRD: LOH low (n = 15)
6×
carboplatin/gemcitabine/iniparib
PE: RCB = residual cancer burden 0
or 1
I: RCB 0/1: 66%
II: RCB0/1: 20%
CHROMOSOMAL ABERRATIONS
Type of study +
ref. Patients Test used + definition HRD Subgroups
Treatment
(total treated) primary endpoint and results
VELIA study
Randomized Phase 3, first line [23]
High grade serous epithelial ovarian,
fallopian tube or primary peritoneal
carcinoma;
No preselection on platinum
sensitivity
MyChoice assay = sum of LOH, TAI
and LTS score;
HRD = total score ≥42
Second definition
HRD = total score ≥33
Three groups
I: g/sBRCA mutated (298)
II: BRCAwt + HRD high (329)
III: BRCAwt with HRD low (372)
Of note:
47% HRD within BRCAwt
CTx + PB + PB maintance
(n = 375) vs.
CTx + veliparib + PB maintance
(n = 383) vs.
CTx + veliparib + veliparib
maintance
(n = 382)
PE: ia PFS, median FU 28 months
I: PFS 34.7 vs. 22.0 months;
HR 0.44 (0.28–0.68)
II: * estimated PFS 21.5 vs. 18.5
months;
HR 0.80 (0.64–1.00)
III: PFS 15.0 vs. 11.5 months;
HR 0.81 (0.60–1.09)
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Table 2. Cont.
Type of Study + ref. Patients Test Used + Definition HRD Subgroups Treatment(Total Treated) Primary Endpoint and Results
PRIMA study
Randomized phase 3, maintenance
therapy after first line therapy [24]
Platinum sensitive high grade serous
or endometrioid ovarian carcinoma,
stage III or IV, platinum sensitive (i.e.,
partial or complete response after
first line platinum-based
chemotherapy)
MyChoice assay = sum of LOH, TAI,
and LTS score;
sBRCA1/2m based on NGS
HRD = total score ≥42
Three groups
I: g/sBRCAm (n = 223);
II: g/sBRCAwt + HRD high (n = 150);
III: g/sBRCAwt + HRD low (n = 360)
Of note:
29% HRD within BRCAwt






PE: PFS, median FU 13.8 months
I: PFS 22.1 vs. 10.9 months;
HR 0.40 (0.27–0.62)
II: PFS 19.6 vs. 8.2 months;
HR 0.50 (0.31–0.83)
III: * estimated PFS 6.1 vs. 6.4 months;
HR 0.68 (0.49–0.94)
SCOTROC4 study (n = 964);
randomized phase 3; first line; a
prespecified subgroup analyses [25]
Untreated stage III/IV epithelial
ovarian, fallopian tube, or primary
peritoneal carcinoma;
first line
Genome-wide SNP data; sum of
LOH, TAI, and LTS score
HRD = total score ≥42
Second definition
HRD = total score ≥33
Three subgroups
I: HRD (incl. sBRCAm) (n = 79)
II: sBRCAm only (n = 47)
III: CCNE1 amplified
Carboplatin/
paclitaxel standard vs. dose
intensified based on nadir platelet
and neutrophil counts
One of the three PE: PFS (n = 225),
median FU not mentioned
I: PFS 16.5 vs. 9.5 months; HR 0.50
(0.34–0.73)
If HRD is defined as ≥33: HR 0.51
(0.36–0.72)
II: PFS 18.9 vs. 11.0 months; HR 0.48
(0.29–0.79)
III: PFS 9.5 vs. 13.2 months; HR 1.56
(1.04–2.34)
PAOLA 1 study, randomized phase 3,
second line [26]
High grade serous or endometrioid
ovarian, fallopian, or primary
peritoneal carcinoma independent of
BRCA status or non-mucinous
epithelial ovarian cancer with a
deleterious gBRCAm; platinum
sensitive after first line
carboplatin/taxane bevacizumab
MyChoice assay = sum of LOH, TAI,
and LTS score.
HRD = total score ≥44
Three subgroups
I: g/sBRCAm (n = 237)
II: BRCAwt + HRD high (n = 152)
III: BRCAwt + HRD low/unknown (n
= 419)
Of note:
27% HRD within BRCAwt
Olaparib + bevacizumab (n = 537) vs.
PB + bevacizumab (n = 269)
for a maximum of 24 months
PE: iaPFS, median FU 22.7 months
I: iaPFS 37.2 vs. 21.7 months; HR 0.31
(0.20–0.47)
II: iaPFS 28.1 vs. 16.6 months; HR
0.43 (0.28–0.66)
III: iaPFS 16.9 vs. 16.0 months; HR
0.92 (0.72–1.17)
NOVA trial, randomized phase 3 [27]
High grade serous epithelial ovarian,
fallopian tube or primary peritoneal
carcinoma; platinum-sensitive (PR or
CR and ≥6 months PFI of last
platinum containing regimen), ≥2
line of CTx
MyChoice assay = sum of LOH, TAI,
and LTS score.
HR = total score ≥42
Three subgroups
I: gBRCAm (n = 201)
II g/sBRCAwt + HRD high (n = 115)
III g/sBRCAwt with HRD low (n =
134)
Of note:
46% HRD within BRCAwt
Niraparib (n = 372)
vs.
PB (n = 181)
Continue until PD or unacceptable
toxicity
PE: PFS, median FU 16.9 months
I: PFS 21.0 vs. 5.5 months; HR 0.27
(0.17–0.41)
II: *estimated PFS 9.0 vs. 4.0 months;
HR 0.38 (0.23–0.63)
III: * estimated PFS 5.8 vs. 3.9 months;
HR 0.58 (0.36–0.92)
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Table 2. Cont.
Type of Study + ref. Patients Test Used + Definition HRD Subgroups Treatment(Total Treated) Primary Endpoint and Results
Study 19
Randomized phase 2 study
[18]
Platinum sensitive grade 2/3 serous
ovarian carcinoma, platinum
sensitive (2–3 lines of platinum and
objective response on last
platinum-based therapy)
maintenance therapy.
MyChoice assay = sum of LOH, TAI
and LTS score.
HRD = total score ≥42
Second definition
HRD = total score ≥33
Three subgroups
I: g/s BRCAm (n = 106);
II: BRCAwt + HRD (n = 139);
III: BRCAwt + no HRD (n = 60)
Of note:




n = 265 in total;
continue
until PD or unacceptable toxicity
PE: PFS, exact median FU not
mentioned
I: PFS in months not mentioned; HR
0.18 (0.10–0.31)
II: PFS in months not mentioned; HR
0.48 (0.18–1.27)
III: PFS in months not mentioned; HR
0.60 (0.31–1.17)
Of note: In subgroup with >6 y PFS,
no specific molecular aberrations
other than high percentage of
g/sBRCA2m
Quadra study Phase 2, single arm
[28]
High grade serous (grade 2 or 3)
epithelial ovarian, fallopian tube or
primary peritoneal carcinoma;
≥3 lines of CTx, measurable disease,
first line platinum-based CTx PFI
must be ≥6 months
MyChoice assay = sum of LOH, TAI,
and LTS score.
HRD = total score ≥42
Three subgroups
I: g/sBRCAm (n = 87)
II g/sBRCAwt + HRD (n = 135)
III g/sBRCAwt + no HRD (n = 195)
Of note:
41% HRD within BRCAwt
Niraparib (n = 463)
until PD or unacceptable toxicity
PE: ia-ORR; median FU 12.2 months
I: ia-ORR 29% (39 vs. 27%)
II: ia-ORR 15% (26 vs. 10%)
III: ia-ORR 3% (3 vs. 4%)
secondary outcome: median OS:
I: median OS 26.0 (18.1-NR) months
II: estimated median OS 14.5 months




randomized phase 2 [29]
Stage II-III, TNBC, patients with
known gBRCA1/2m were excluded
MyChoice assay = sum of LOH, TAI,
and LTS score.
BRCA testing on blood and tumor
HRD = total score ≥33 or
g/sBRCA1/2m
Two subgroups
I: HRD (incl g/sBRCAm) (n = 74)
II: no HRD (n = 30)
4× Cisplatin (n = 56)
vs.
12× paclitaxel (n = 48)
Two PE: 1st RCB0/1; 2nd pCR
I: RCB0/1: 23% vs. 12%; OR 2.22
II: RCB0/1: 29% vs. 31%%; OR 0.90
Of note, 6 (of the 7) sBRCAm tumors
were randomly allocated to CDDP
with only 1 RCB 0/1 (17%)
I: pCR: 13% vs. 6%; OR 2.32
II: pCR: 14% vs. 23%%; OR 0.55
GEPARSIXTO
trial, randomized phase 3, post hoc
analyses in TNBC only [30]
TNBC, stage II-III
MyChoice assay = sum of LOH, TAI,
and LTS score.
HRD = total score ≥42 or gBRCA1/2m
Two subgroups
I: HRD or g/sBRCAm (n = 136)
II; no HRD and BRCAwt (n = 57)
Paclitaxel/
pegylated doxorubicine/
bevacicumab (n = 157)
vs. paclitaxel/
pegylated doxorubicine/
bevacicumab/carboplatin (n = 158)
PE: pCR (ypT0N0)
I: pCR 33.9% vs. 63.5%; OR 3.4
(1.7–6.9)
II: pCR 20.0% vs. 29.6%; OR 1.7
(0.5–5.7)
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Type of Study + ref. Patients Test Used + Definition HRD Subgroups Treatment(Total Treated) Primary Endpoint and Results
TNT Trial. Randomized phase 3, first
line [31]
TNBC advanced setting, no CTx for
advanced setting
MyChoice assay = sum of LOH, TAI,
and LTS score.
HRD = total score ≥42
Two subgroups
I: gBRCAm (n = 43)
II: HRD (independent of gBRCA
status) (n = 81)
III: HRD (incl gBRCAm) (n = 86)
Carboplatin (n = 188)
ns
Docetaxel (n = 188)
PE ORR difference between
carboplatin vs. docetaxel per group
I: ORR difference: 34.6% vs. −6.4% p
interaction 0.01
II: ORR difference: −2.2% vs. 2.2% p
interaction 0.75
III: ORR difference: 5.1% vs. −1.8% p
interaction 0.63
TBCRC009 study, phase 2, single arm,
posthoc analysis [32]
TNBC, maximum of one line CTx in
advanced setting
LOH by NGS assay; chromosomal
breaks by another assay
Sum scores of the two assays
HRD-LOH and HRD-LST was used
as continues variable; no HRD
definition.
Posthoc analysis of difference
between responder (CR and PR) vs.
non-responders (SD or PD)
carboplatin (n = 43) and cisplatin (n =
43)
PE ORR
Sum score HRD-LOH and HRD-LST
was statistically significantly higher
among responder than
non-responders gBRCAwt TNBC
patients (12.7 vs. 5.1; p = 0.032)
No data on ORR for HRD-LOH or
HRD-LST scores separately
SWOG S9313
study randomized phase 3, post hoc
analyses in TNBC [33]
High risk N0, or low risk n+ primary
breast cancer, adjuvant
chemotherapy.
MyChoice assay = sum of LOH, TAI,
and LTS score.
HRD = total score ≥42 or sBRCA1/2m
Two subgroups
I: HRD (incl. sBRCA1/2m)




PE: (5-y) DFS, exact median FU not
mentioned
I: 5-y DFS: 65.2% vs. 78.7%; HR 0.72
(0.51–1.00)
II: 5-y DFS: 65.2% vs. 80.5%; HR 0.64
(0.43–0.94)
CTx = chemotherapy; DFS = disease free survival; FU = follow-up; g = germline; HRD homologous recombination deficiency; HRR = homologous recombination related; iaPFS = investigated assessed PFS; LOH
loss of heterozygosity; LTS = large scale state transition score; ORR = objective response rate; OS = overall survival; PE = primary endpoint; PFS = progression free survival; PB = placebo; RCB = residual cancer
burden; s = somatic; TAI = telomeric allelic imbalance; TNBC = Triple negative breast cancer; wt = wild type; * estimated only in case this was possible on the basis of existing data.
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The high percentage of LOH appears to be associated with a higher likelihood of
response to DSB-inducing agents. However, it is not distinctive enough to withhold these
drugs from patients with low LOH tumors. Therefore, additional chromosomal aberrations
have been added to the level of LOH to identify HRD tumors. Deletion of stretches larger
than 15 Mb but smaller than the whole chromosome [34], telomeric allelic imbalance
(TAI), and large-scale transitions (LST) were found more often in BRCA1/2 associated
tumors [34,35]. TAI indicates that the copy numbers of the paternal and maternal alleles
are not equal in the sequences close to the telomere. LST denotes a group of chromosomal
aberrations involving large chromosomal regions resulting from DSBs more than 10 Mb
apart [35]. The HRD score can then be calculated based on LOH, TAI, and LST. The lower
limit of this test to select HRD was determined based on the lowest score found in proven
BRCA1/2 associated tumors. In a retrospective study of chemotherapy, naive breast cancer
(n = 497) and ovarian cancer (n = 561) patients with known BRCA1/2 status were used to
set the cut-off value at≥42 [36]. Thus, all non-BRCA1/2 mutated tumors that scored≥42 on
this test were considered to be HRD tumors. A similar HRD test is currently commercially
available from Myriad, referred to as the MyChoice assay.
A lot of clinical data have been collected with this commercial MyChoice assay,
especially among patients with ovarian cancer who were treated with PARPi (Table 2).
From these studies, a number of things can be concluded. First, there is a clear prognostic
value of the MyChoice assay. Ovarian cancer patients with a germline (blood) or somatic
(tumor) BRCA1/2 gene mutation had the best prognosis compared to non-BRCA1/2 tumors.
Furthermore, tumors without BRCA1/2 mutations with a high HRD score had a more
favorable prognosis than those tumors with a low HRD score (Table 2). There is a similar
trend with regard to the predictive value of the MyChoice assay. Here again, the presence
of a BRCA mutation had the strongest predictive value for selecting tumors sensitive to a
PARPi. This was followed in descending strength by an high HRD score and finally an low
HRD score. In other words, non-BRCA1/2 tumors with a high HRD score had an increased
chance of PARPi sensitivity. On the other hand, having a low HRD score in a non-BRCA1/2
tumor was not selective enough to completely omit a PARPi in this group, because there
was still demonstrable added value compared to placebo treatment. This also applied to
the non-commercial variant of this HRD assay used in a pre-specified subgroup analysis
of the large SCOTROC4, phase III study among untreated stage III/IV epithelial ovarian,
fallopian tube, or primary peritoneal cancers [25]. Therefore, there is currently no clear
added value for determining this type of HRD test to select patients who do or do not
benefit from a PARPi in ovarian cancer patients.
In view of the broad effectiveness of PARPi in ovarian cancer patients, it might be
better to look for a biomarker that selects those patients that do not benefit from this
treatment than the current approach that tries to identify the group that does benefit. An
attempt has been made to do so by lowering the value of the score that determines the
classification of HRD high and HRD low. Although Hodgson et al. [18] were the first to
show some evidence that lowering this value from ≥42 (standard) to ≥33 for defining
the HRD-high group was indeed possibly more distinctive, this was not confirmed in the
large randomized phase 3 VELIA study [23], and the pre-specified subgroup analysis of
the SCOTROC 4 study [25].
The MyChoice assay has also been investigated among breast cancer patients in sev-
eral studies [29–33] (Table 2). The prognostic value of the MyChoice assay was clearly
demonstrated in a post hoc subgroup analysis of the large randomized SWOG S9313 phase
3 study, in which concomitantly administrated adjuvant doxorubicin with high dose cy-
clophosphamide was compared with similar drugs sequentially administrated [33]. The
disease-free survival (DFS) was better for the 67% triple negative breast cancer patients
with an HRD phenotype compared to non-HRD (10-year DFS: 70.5 vs. 58.3% respectively),
and also when patients with sBRCA1/2 mutation were excluded (10-year DFS: 74.4 vs.
58.3%, respectively). Unfortunately, the predictive value of the HRD test could not be
studied, as both treatment arms underwent an equal total dose of double stranded DNA
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break-inducing agents. In the neoadjuvant Geparsixto study comparing the triplet pacli-
taxel, pegylated doxorubicin, and bevacizumab with the triplet plus carboplatin, an HRD
phenotype based on the MyChoice assay more likely resulted in a pathological complete
remission (pCR) when carboplatin was added to the triplet [30]. However, the interaction
between therapy and HR status was not statistically significant. In two other studies
comparing monotherapy taxanes to monotherapy platinum-containing therapy [29,31],
the MyChoice assay did not show predictive value. In the fourth study [32], there was no
platinum-free treatment arm, and therefore the predictive value of the assay could not be
properly investigated.
Thus, in both high-grade serous or endometrial ovarian cancer and triple negative
breast cancer, the predictive value of the MyChoice assay appears to be limited and should
in any case not be used in routine clinical practice for the selection of HRD tumors.
5. Genomic Scars Resulting from HRD
Genomic alterations can be the result of the HRD phenotype. Imprecise repair after
DNA damage due to a dysfunctional HR pathway leads to mutations. These genomic
alterations can be the direct consequence of the DNA repair defect in the tumor, or they
may have been caused by up- or downregulation of other DNA repair pathways as compen-
sation for the original DNA repair defect. These alterations can be used as biomarkers for
the HRD phenotype. Whole genome sequencing (WGS) data are used to detect the precise
changes in nucleotide sequence that have accumulated in the tumor DNA during the
course of tumor evolution. This combination of various alterations is collectively referred
to as ‘genomic scars’ [37].
The pattern of these genomic scars was analyzed using an unbiased computational
approach. The first sign that scars could be used to identify causes of DNA alterations
and possible underlying DNA repair defects came from a systematic analysis of point
mutations [38]. Each nucleotide substitution was classified based on the change itself and
the nucleotides preceding and following the point mutation. Subsequently, 21 patterns of
substitution mutations were characterized, also known as ‘mutational signatures’. Later
on, more patterns have been added to this original set and some patterns have been linked
to specific DNA damaging agents or DNA repair defects [39]. Signature 3 was specifically
linked to BRCA1/2 deficiency. A similar enrichment for signature 3 was found for PALB2
and RAD51C mutations or epigenetic silencing of the BRCA1 or RAD51C promoter, but
not for inactivation of other cancer-associated genes, such as CHEK2 and ATM [40]. In all
cases, this association with signature 3 could not be used to select individual HRD tumors,
because its prevalence was quite variable. Some tumors containing BRCA mutations did
not show a high contribution of signature 3, while several other (probably non-HRD)
tumors showed a high contribution of this signature [40].
Another important characteristic of BRCA deficient tumors, in addition to signature 3,
is a pattern of deletions with short stretches of sequence homology (also termed ‘microho-
mology’) at the junctions [41]. Subsequently, more features of DNA sequence changes have
been characterized, including DNA rearrangements and deletions [42]. These character-
istics have been combined in the computational algorithm HRDetect that was originally
trained on breast cancer WGS [43]. It integrates the values for these characteristics, where
scores above 0.7 indicate HRD. Using this cut off, almost 99% of the bi-allelic BRCA1/2
mutations in the training set were detected by the algorithm.
The first evidence for clinical validation of the HRDetect assay came from nine pa-
tients with triple negative breast cancer who underwent biopsies prior to neoadjuvant
chemotherapy [43]. Five tumors with a high HRDetect score showed a pathologically
complete remission in response to epirubicine-containing chemotherapy, a topoisomerase
2 inhibitor that leads to, among other things, double-stranded DNA breaks. The other
four tumors with a low HRDetect score all showed residual disease after neoadjuvant
chemotherapy. In the ongoing population-based observational SCAN-B study, the prog-
nostic value of the HRDetect assay was subsequently demonstrated in 145 triple negative
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breast cancer patients [44]. For example, multivariable analysis showed a statistically
significant and clinically relevant 69% lower risk of distant relapse-free survival in patients
with a HRDetect high compared to HRDetect low score (HR 0.31 (0.13–0.76)). However, a
convincing predictive value for preferential benefit of anthracycline-containing therapy
could not yet be demonstrated in the HRDetect high (62%) compared to the HRDetect low
score tumors (38%). This may partly be the result of the relatively short median follow-up
duration (<5 years) and the retrospective nature of this study.
The HRDetect assay was also investigated in the exploratory neoadjuvant RIO study in
which 43 patients with triple negative breast cancer were treated with the PARPi rucaparib
for two weeks prior to neoadjuvant chemotherapy or resection [45]. As in the SCAN-
B study, the majority (69%) of the tumors showed a high HRDetect score, suggestive
of a HRD phenotype. In addition, patients with a high score HRDetect tumor had a
lower tumor burden (measured as lower levels of ctDNA) after 2 weeks of treatment with
the PARPi rucaparib than patients with a low HRDetect score. However, there was no
difference in the probability of a Ki67 reduction <50%, the primary endpoint of the study,
between the tumors with an HRDetect high or an HRDetect low score. Further research is
necessary to determine the predictive value of HRDetect for sensitivity to double strand
DNA break inducers.
A similar test based on genomic scars is the Classifier of Homologous Recombination
Deficiency (CHORD). This algorithm was developed using more than 3000 tumor WGS
sets covering 31 types of cancer. Deletions with microhomology at the junction were most
predictive for the HRD probability. The majority of tumors marked as HRD by the CHORD
test were caused by biallelic inactivation of BRCA1, BRCA2, RAD51C or PALB2. However,
85 out of 211 identified HRD tumors did not harbor any of these mutations [46]. This
test appears to be roughly equivalent to HRDetect, although currently no data have been
published regarding the predictive value of the CHORD test in clinical practice.
6. The BRCA-Like Classifier as Predictor for HRD
Loss of function mutations in the BRCA1 and BRCA2 genes not only increase the
chance of developing cancer, but they also decrease the viability and proliferative capacity
of normal cells. Mutations in other genes are required to compensate for this selective
disadvantage (for example inactivation of the TP53 gene [47]). In other words, HRD
can cause selective pressure towards a loss or gain of genes and (parts of) chromosomes.
Therefore, specific chromosomal gains and losses have been analyzed to obtain evidence
for HRD in tumors.
Initially, Linn and colleagues developed a BRCA1-like classifier for the selection of
breast tumors with a HRD phenotype using a comparative genomic hybridization (CGH)
assay [48]. In a retrospective analysis of a randomized phase III trial among stage III HER2
negative breast cancer patients, this BRCA1-like classifier proved to be a strong predictive
factor for better outcomes after treatment with high-dose alkylating chemotherapy with au-
tologous stem cell transplantation compared to standard anthracycline-containing therapy
(risk of recurrence in BRCA1-likeCGH HR 0.12 (0.04–0.43) vs. non-BRCA1-likeCGH HR 0.78
(0.50–1.20); p interaction 0.006) [49]. The incidence of HRD tumors based on the BRCA1
like classifier in this study was 33%, among the HER2 negative breast cancers. Among the
triple negative breast cancer patients, this was much higher (57%), which is comparable
to the percentages of HRD among triple negative tumors demonstrated by other HRD
tests, such as the MyChoice assay. Extension of the BRCA classifier with a BRCA2-like
CGH assay showed a higher percentage of HRD tumors [50]. This was, however, almost
entirely explained by a HRD phenotype detected among ER-positive tumors (3% HRD
based on the BRCA1-likeCGH classifier and 22% HRD tumors based on the BRCA1/2-like
classifier). In view of the much higher percentage of HRD tumors among triple negative
breast cancer, the BRCA1-likeCGH classifier was further investigated in this group. The
predictive value of this classifier was confirmed in a retrospective case control study where
the BRCA1-likeCGH tumors benefited from high-dose alkylating chemotherapy (overall
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survival in BRCA1-likeCGH HR 0.15 (0.03–0.83) vs. non-BRCA1-likeCGH HR. 0.93 (0.52–1.64);
p interaction 0.045)) [51]. In a third retrospective study, however, the predictive value of
the BRCA1-likeCGH classifier could not be confirmed [52]. In the ongoing prospective ran-
domized phase 3 SUBITO study (NCT02810743), currently running in the Netherlands and
France, the definitive predictive value of the BRCA1-likeCGH classifier will be determined.
7. Gene Expression Profiles as Predictor for HRD
Changes in chromosomal content will also affect gene expression levels and thus can
be used to identify HRD tumors. On the basis of publicly available microarray datasets
of 61 proven ovarian carcinomas, of which 34 have a proven germline BRCA mutation,
a 60 gene profile was established that distinguished BRCA from non-BRCA tumors [53].
This gene profile was then tested in 70 ovarian cancer patients treated primarily with
platinum-based chemotherapy and resection. As with other HRD tests, this profile showed
a favorable prognosis of those tumors classified as HRD compared to non-HRD. However,
no information on the predictive value could be given, as all patients underwent platinum-
based therapy. A gene expression profile was also established in breast cancer patients,
distinguishing BRCA-like (based on copy number variations) and non-BRCA-like breast
tumors [54]. Of the 116 Her2 negative primary breast cancer patients, 47% showed a gene
expression profile consistent with HRD (78% among triple negative and 14% among the
ER+, Her2− breast tumors). This gene expression profile seemed predictive of a favorable
response to the addition of the PARPi veliparib and carboplatin to paclitaxel compared to
paclitaxel alone; however, this effect could only be demonstrated in the ER+, Her2− breast
tumors. Furthermore, both gene expression profile studies were performed on tumors that
had not previously been treated with chemotherapy. The question is what the predictive
value of such gene expression profiles will be in larger studies, as well as the value of
such profiles when they are determined on tumor material that has already undergone
chemotherapy treatment.
8. Functional Tests
Intuitively, a functional test should be the ultimate HRD assay. The most straightfor-
ward form of functional testing is drug sensitivity screening of cell lines, organoids or tissue
slice [55]. Although such tests may be able to predict patient outcome to therapy, they
can be time consuming and they do not report on the HRD status of the tumor. Therefore,
alternative functional assays have been developed for HRD selection. Most functional
biomarkers in this respect are based on measuring RAD51 accumulation on DSB, generally
referred to as RAD51 foci. RAD51 is involved in the HR pathway downstream from the
BRCA1/2 proteins (see Figure 1). The RAD51 protein that covers the single-stranded DNA
at double strand breaks can be visualized as RAD51 foci after immunofluorescent staining
(Figure 1 step 4). These foci are absent in BRCA1/2 deficient tumors, since RAD51 is not
loaded onto single-stranded DNA ends in the absence of BRCA1/2 [56].
8.1. HR Pathway Proteins after In Vivo Treatment
As a first approach, HR pathway protein accumulation could be determined on tumor
biopsies collected before and after patients had received neoadjuvant treatment with DSB-
inducing chemotherapy. In the first study, biopsies of 68 breast cancer patients undergoing
neoadjuvant anthracycline-based chemotherapy were taken before treatment and 24 h after
the first chemotherapy course [57]. The absence of RAD51 foci in treated samples was taken
as a sign of HRD. As RAD51 foci formation is confined to cells in the S and G2 phases of
the cell cycle, geminin was used as a marker to identify this cell population. The advantage
of this approach is that the absence of RAD51 foci in geminin-positive tumor cells actually
reflects an inability to perform HR and is not due to the absence of proliferation in the
biopsy. Overall, 26% (15/57) of the breast tumor samples showed a low RAD51 score 24 h
after anthracycline-based chemotherapy. Compared to a high RAD51 score, the tumors
with low RAD51 score post chemotherapy showed a significantly higher percentage of
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pathological complete response after anthracycline-based neoadjuvant chemotherapy (i.e.,
33% vs. 3%, p = 0.001).
In another study, tumor biopsies were obtained from 60 primary breast cancer patients
24 h after treatment with epirubicin and cyclophosphamide (EC) [58]. Tumor samples were
immunohistochemically stained for RAD51, γH2AX, conjugated ubiquitin, and BRCA1
foci. The results of these stainings were pooled and converted to a DNA damage response
(DDR) score of 0–4. The lowest score (0) was considered a measure of HRD. There was
a significant inverse correlation between the DDR score and the mean tumor volume
reduction determined by helical computed tomography (CT) after four courses of EC
chemotherapy. The absence of RAD51 foci before or after one course of chemotherapy did
not correlate with significantly more tumor reduction compared to tumors with RAD51
foci present. Importantly, RAD51 foci staining was not corrected for geminin staining,
suggesting that this group contains false negative tumors.
8.2. RAD51 Foci after Ex Vivo Treatment
An important further improvement of functional testing is the induction of DNA
double strand breaks before starting treatment of patients, in order to prevent exposure to
therapies that may not provide any benefit. Most commonly, fresh tumor tissue is collected
and DNA breaks are induced ex vivo by ionizing radiation (IR). Subsequently, the tumor
tissue is incubated for a few hours to allow accumulation of RAD51 protein at the breaks.
A pilot study assessed the feasibility to measure the formation of BRCA1, FANCD2
and RAD51 foci after IR in small pieces of breast tumors ex vivo [59]. RAD51 foci in
biopsies indeed could be scored, although quantification was more difficult than in cell
lines. A follow up study used the same method in 56 fresh breast cancer patient samples.
Ki67 was added as a marker for proliferation in this study, to ensure tumor cells were not
quiescent [60]. In total, 22% of the tumors were scored as HRD. Nine HRD and 15 HRP
tumors were further characterized using genomic scars and mutational signatures in order
to compare this method to other HRD biomarkers. As expected, HRD tumors defined by
the RAD51 foci test had a significantly higher level of BRCA1/2 scars and scored higher on
LOH, LST and insertions and deletions than HRP tumors.
As a further improvement, geminin was added to identify S/G2 cells [61] RAD51
foci formation was first investigated in PDX tumors of known BRCA status. Tumors with
BRCA1 and BRCA2 mutations as well as promoter methylation all showed that less than
20% of geminin-positive cells had RAD51 foci, whereas BRCA wild type tumors showed
foci in more than 50% of the S/G2 cells. This repair capacity (RECAP) test found that
19% of the unselected primary breast tumors (out of 125 breast cancer cases) showed a
HRD phenotype, which could be explained by BRCA1/2 mutations or BRCA1 promoter
hypermethylation in most cases [62,63]. However, approximately one third of these HRD
tumors did not show clear genetic or epigenetic defects in these genes, suggesting that
more than only BRCA-deficient tumors may benefit from DSB-inducing therapies, such
as PARPi.
A subsequent study on biopsies from metastatic breast cancer patients (n = 44) showed
that the RECAP test was also feasible in this setting. Importantly, 30% of these biopsies
showed HRD, suggesting that an even higher percentage of patients might benefit from
PARP inhibitor treatment in metastasized breast cancer. Interestingly, three patients in
the HRD group, all having a BRCA defect, donated a biopsy before the start of treatment
and after progression with DNA double strand break-inducing chemotherapy. Where pre-
treatment biopsies were all HRD, post-treatment biopsies of the same patients showed clear
induction of RAD51 foci, indicating that this functional assay indeed measures HR capacity
in real time [64]. RECAP scores were obtained in 82% of all cases and were available within
one week, which makes this test in principle compatible with clinical practice.
This RECAP assay is also feasible for other cancer types. The RECAP assay could
also be applied in tissue slices and ascites-derived cancer cells from ovarian tumors [65].
In this first study, the authors found that 10 out of 39 high grade serous ovarian tumors
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were HRD, mostly because of BRCA gene defects. The exact same test has also been used
for endometrial cancer. The tumors which histologically resembled ovarian carcinomas
more frequently showed HRD rather than endometrioid subtypes [66]. Ascites-derived
tumor cells from several other cancer types have also been used for studying RAD51 foci
formation [67,68]. Although cell cycle controls are missing here, the data suggest that HRD
can also be found in several other tumor types.
8.3. RAD51 Foci in Untreated Tumors
A drawback of these functional RAD51 foci assays is the requirement for fresh biop-
sies. Therefore, another method to use RAD51 foci as a potential biomarker without prior
induction of DNA damage was explored. This approach relies on the presence of endoge-
nous DNA double strand breaks in the tumor at the moment of biopsy collection. RAD51
nuclear foci in untreated tumor samples were studied in two small studies. In a cohort of
23 breast cancer patients without a gBRCA mutation but with high suspected hereditary
breast cancer, less than 10% RAD51 foci were detected in 14 of 23 tumors [69]. Eleven of
the 14 patients with a low RAD51 tumor had a gPALB2 mutation. In the three other tumors
with low RAD51 foci, no BRCA1 nuclear foci could be detected, possibly due to BRCA1
promoter methylation. In the nine tumors with RAD51 foci >10%, BRCA1 foci were always
detected. In a second study, RAD51 foci tumor staining was performed in seven patients
before starting treatment with a PARPi [70]. Three patients showed primary resistance to
the PARPi and had RAD51 foci detectable in the tumor prior to treatment initiation and
the other four patients with PARPi sensitivity had low RAD51 foci before PARPi started.
These results provide some evidence that RAD51 foci in untreated tumor tissue may be an
expression of HRD, but the data are not completely consistent and have been studied in a
very small number of patient samples so far.
Functional tests have not been extensively tested yet to link biomarkers to predictive
value in clinical outcomes. At this moment, several clinical trials have started using RAD51
foci as potential biomarker for HRD selection. If RAD51 foci formation ex vivo can indeed
be linked to the clinical outcome of patients, the possibilities for implementation into the
clinical decision making should be explored.
9. Conclusions and Future Directions
Although several assays have been developed to identify HRD tumors, it is currently
not clear which one is the most promising candidate for implementation in clinical practice.
The most important first question is whether a test has sufficient predictive value for patient
selection. These data are currently lacking for most tests or test results are suboptimal.
The MyChoice test was used in several clinical trials in which HRD groups respond better
to therapy than the HRP groups, but the non-BRCA HRD group benefits much less from
PARPi treatment than the gBRCA-mutated patients. Furthermore, the HRP subgroup
showed survival benefit on PARPi, indicating that withholding treatment based on this
test is debatable. Therefore, the first efforts should be geared towards generating sufficient
clinical validation of the various tests. It will be important to determine whether the cut off
values for the selection of HRD tumors can be optimized in the various tests. Inclusion
of too many false positives would decrease the PFS when compared to gBRCA mutated
subgroups. This is because HRP patients will be treated with a PARPi. However, this might
be better than too many false negatives. In that way, the group of PARPi treatments might
decline, but a lot of patients will not receive PARPi treatment even though they would
benefit from it.
A problem for most tests is the reversion of the HRD phenotype upon treatment. This
can, for instance, be caused by mutations and epigenetic silencing [71]. Sequencing-based
tests such as the BRCA1/2 classifier and HRDetect/CHORD determine the total mutation
load acquired over the course of tumor evolution, implying that resistance due to prior
treatment with DNA double strand break-inducing agents might not show up in these
sequencing-based tests. For determination of the HR phenotype, the functional tests may
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be best in predicting therapy response as a real time indicator of the phenotype. Direct
clinical validation of this prediction should be obtained in prospective clinical trials.
In addition to the clinical validation of the tests, several other factors will also con-
tribute to their chances of being implemented in clinical decision making. Important
considerations are the type of starting material needed, turnaround time of the assay, and
cost. FFPE or frozen specimens are most easily handled as the starting material, while
functional assays requiring fresh tumor tissue pose a logistic challenge, especially for
peripheral hospitals that would need to transport this fresh material to dedicated test
laboratories. Therefore, the spontaneous RAD51 foci assay would be much more practical
than the RECAP assay, as it does not require handling fresh tumor tissue. Turnaround time
is another important factor: test results should be available within two weeks in order to be
included in the decision making process. This is possible for most tests, although it is a chal-
lenge for WGS approaches. Dedicated sequencing facilities and bioinformatics pipelines
would be required to facilitate this time line. Finally, assay costs are also important to select
the preferred test. Panel sequencing or shallow Next Generation Sequencing (NGS), as
required for the BRCA1/2 classifier) are relatively inexpensive, while good coverage WGS
(required for HRDetect and CHORD) is currently the most expensive option.
It is clear that the first step is the clinical validation of the various tests. Several studies
have been carried out or are ongoing, but this did not yet result in a gold standard. An
interesting approach for clinical validation and direct comparison of the various tests
would be a large multicenter trial, in which patients of a certain cancer type are screened
for the HRD phenotype using all potential biomarkers. When scored HRD for at least one
of the biomarkers, this patient will be considered HRD. Clinical response to PARPi should
be analyzed for all different biomarkers. This multicenter clinical trial might also be used
to determine cut off values for which the predictive value is optimal. It will be especially
important to carry out the functional assay in the various trials, as it requires fresh biopsy
material, which cannot be obtained retrospectively. Together with considerations of starting
material, turnaround time, and cost, this should then result in the selection of the most
optimal HRD test for patient stratification.
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